FAQ

acetylacetoin reductase (NADH)

Known as: AACR II 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2018
0500100019992018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Atezolizumab (Tecentriq, MPDL3280A; Genentech/Roche) is an FcγR binding-deficient, fully humanized IgG1 mAb designed to interfere… (More)
Is this relevant?
Review
2017
Review
2017
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment of advanced renal cell carcinoma… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Purpose: Patients with pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show variable responses to platinum-based… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.
Humans consider themselves discrete autonomous organisms, but recent research is rapidly strengthening the appreciation that… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2016
Review
2016
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both… (More)
Is this relevant?
Review
2016
Review
2016
Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.
Metabolite profiling is being increasing employed in the study of prostate cancer as a means of identifying predictive… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
PURPOSE Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
PURPOSE To identify baseline peripheral blood biomarkers associated with clinical outcome following ipilimumab treatment in… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1.
Long noncoding RNAs (lncRNA) have been implicated in human cancer but their mechanisms of action are mainly undocumented. In this… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China.
One of several challenges in design of clinical chemoprevention trials is the selection of the dose, formulation, and dose… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?